(Q36599070)

15 August 2017

1 reference

title

Optical coherence tomography in multiple sclerosis (English)

1 reference

optical coherence tomography

15 August 2017

0 references

1 reference

9

Laura Balcer

1 reference

15 August 2017

3

Robert Zivadinov

1 reference

15 August 2017

Elliot Frohman

1

1 reference

15 August 2017

Fiona Costello

2

1 reference

15 August 2017

Olaf Stuve

4

1 reference

15 August 2017

Amy Conger

5

1 reference

15 August 2017

Heather Winslow

6

1 reference

15 August 2017

Anand Trip

7

1 reference

15 August 2017

Teresa Frohman

8

1 reference

15 August 2017

1 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

10

1 reference

15 August 2017

853-863

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Disease-modifying Therapies for Multiple Sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Multiple sclerosis--the plaque and its pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

The neuro-ophthalmology of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

The retinal nerve fiber layer, neuroretinal rim area, and visual evoked potentials in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Insidious atrophy of retinal nerve fibers in multiple sclerosis. Funduscopic identification in patients with and without visual complaints.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Visual acuity in optic atrophy: a quantitative clinicopathological analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Quantitative studies of retinal nerve fiber layer defects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Retinal pathologic changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Detection of optic nerve atrophy following a single episode of unilateral optic neuritis by MRI using a fat-saturated short-echo fast FLAIR sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Irreversible disability and tissue loss in multiple sclerosis: a conventional and magnetization transfer magnetic resonance imaging study of the optic nerves

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

A serial MRI study following optic nerve mean area in acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optic neuropathy in multiple sclerosis; optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Diagnostic ability of optical coherence tomography with a normative database to detect localized retinal nerve fiber layer defects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Diagnostic capability of optical coherence tomography in evaluating the degree of glaucomatous retinal nerve fiber damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Evaluation of the effect of aging on retinal nerve fiber layer thickness measured by optical coherence tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Evaluation of image artifact produced by optical coherence tomography of retinal pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optical coherence tomography to detect and manage retinal disease and glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Quantitative analysis of axonal loss in band atrophy of the optic nerve using scanning laser polarimetry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optic nerve involvement and diplopia as initial manifestations of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Contrast sensitivity and other vision tests in the optic neuritis treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Subclinical Visual Involvement in Multiple Sclerosis: A Study by MRI, VEPs, Frequency-Doubling Perimetry, Standard Perimetry, and Contrast Sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Quantifying axonal loss after optic neuritis with optical coherence tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optical coherence tomography: measuring in-vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Imaging the optic nerve in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Assessment of optic nerve damage in multiple sclerosis using magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Serial magnetization transfer imaging in acute optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Continuing optic nerve atrophy following optic neuritis: a serial MRI study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Diffusion-weighted imaging of the human optic nerve: a new approach to evaluate optic neuritis in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optic nerve diffusion tensor imaging in optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Visual activation patterns in patients with optic neuritis: an fMRI pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

The T lymphocyte in experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Quantitative analysis of labelled inner retinal proteins in experimental optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Axonal transport reductions in acute experimental allergic encephalomyelitis: qualitative analysis of the optic nerve

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Local enhancement of major histocompatibility complex (MHC) class I and II expression and cell infiltration in experimental allergic encephalomyelitis around axotomized motor neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Damage to bulbospinal serotonin-, tyrosine hydroxylase-, and TRH-containing axons occurs early in the development of experimental allergic encephalomyelitis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Axonal cytoskeleton changes in experimental optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Restricted immune responses lead to CNS demyelination and axonal damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Demyelination and axonal damage in a non-human primate model of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Optical coherence tomography (OCT) findings in normal retina and laser-induced choroidal neovascularization in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Quantitative evaluation of ischemia-reperfusion injury by optical coherence tomography in the rat retina

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Progressive change of optical coherence tomography scans in retinal degeneration slow mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

Ocular tissue imaging using ultrahigh-resolution, full-field optical coherence tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970573-7

7 January 2021

10.1016/S1474-4422(06)70573-7

Identifiers

DOI

1 reference

15 August 2017

1 reference